Related references
Note: Only part of the references are listed.Use of PD-1 inhibitor tislelizumab in the treatment of advanced pulmonary sarcomatoid carcinoma: A case report
Li Xu et al.
THORACIC CANCER (2022)
Survival Analysis and Prediction Model for Pulmonary Sarcomatoid Carcinoma Based on SEER Database
Mingjing Chen et al.
FRONTIERS IN ONCOLOGY (2021)
Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma
Charlotte Domblides et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
Lin Shen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
A High PD-L1 Expression in Pulmonary Pleomorphic Carcinoma Correlates with Parietal-pleural Invasion and Might Predict a Poor Prognosis
Maiko Naito et al.
INTERNAL MEDICINE (2019)
PD-L1 and CD47 co-expression in pulmonary sarcomatoid carcinoma: a predictor of poor prognosis and potential targets of future combined immunotherapy
Zhenlin Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2019)
Prospect of immunotherapy combined with anti-angiogenic agents in patients with advanced non-small cell lung cancer
Hongge Liang et al.
CANCER MANAGEMENT AND RESEARCH (2019)
The binding of an anti-PD-1 antibody to FcγRI has a profound impact on its biological functions
Tong Zhang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles
Takahiro Nakagomi et al.
Oncotarget (2018)
Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling
Alexa B. Schrock et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor
Xinru Chen et al.
TRANSLATIONAL ONCOLOGY (2017)
Clinical Significance and Next-Generation Sequencing of Chinese Pulmonary Sarcomatoid Carcinoma
Xin Li et al.
SCIENTIFIC REPORTS (2017)
The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report
Yoko Matsumoto et al.
CASE REPORTS IN ONCOLOGY (2017)
MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non-Small Cell Lung Carcinoma with Poor Prognosis
Joanna H. Tong et al.
CLINICAL CANCER RESEARCH (2016)
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations
Xuewen Liu et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Deep Sequencing Analysis Reveals That KRAS Mutation Is a Marker of Poor Prognosis in Patients with Pulmonary Sarcomatoid Carcinoma
Filippo Lococo et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Scientific Advances in Lung Cancer 2015
Anne S. Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Molecular characterization of pulmonary sarcomatoid carcinoma: analysis of 33 cases
Simone B. S. P. Terra et al.
MODERN PATHOLOGY (2016)
High-throughput somatic mutation profiling in pulmonary sarcomatoid carcinomas using the LungCarta™ Panel: exploring therapeutic targets
V. Fallet et al.
ANNALS OF ONCOLOGY (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Sarcomatoid Carcinoma of the Lung: A Model of Resistance of Chemotherapy
Imane Ouziane et al.
NORTH AMERICAN JOURNAL OF MEDICAL SCIENCES (2014)
Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma
Thibault Vieira et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Outcomes of sarcomatoid carcinoma of the lung: A Surveillance, Epidemiology, and End Results database analysis
Sai Yendamuri et al.
SURGERY (2012)
Pulmonary Sarcomatoid Carcinomas: A Practical Overview
Giuseppe Pelosi et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2010)
Pulmonary Pleomorphic Carcinoma A Clinicopathological Study Including EGFR Mutation Analysis
Kyoichi Kaira et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Sarcomatoid carcinoma of the lung: A predictor of poor prognosis
Linda W. Martin et al.
ANNALS OF THORACIC SURGERY (2007)
Share Paper
